Virax is due to file a half yearly report within the next week or so - in which case chairman, Dr Wayne Millen, will have an opportunity to update the market on the progress of the company's strategic review of IP assets including blockbuster lung cancer candidate Co-X-Gene/TG4010.
Virax is due to file a half yearly report within the next week...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.001(3.57%) |
Mkt cap ! $46.40M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.8¢ | 2.7¢ | $2.318K | 83.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 504704 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 2243930 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| VHL (ASX) Chart |